CROI 2013: Advances in antiretroviral therapy

Topics in Antiviral Medicine

Volumn 21, Issue 2, 2013, Pages 75-89

  Taylor, Barbara S ^a   Wilkin, Timothy J ^b   Shalev, Noga ^c   Hammer, Scott M ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Antiretroviral; Cascade of care; CROI; Cure; HIV; Resource limited; Therapy; Treatment

Indexed keywords

ABACAVIR; BEVIRIMAT; CENICRIVIROC; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CREATININE; DIDANOSINE; DOLUTEGRAVIR; DORAVIRINE; EFAVIRENZ; EMTRICITABINE; HISTONE DEACETYLASE; INTERLEUKIN 7; LAMIVUDINE; LOPINAVIR; MARAVIROC; METHADONE; NELFINAVIR; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; ROMIDEPSIN; TENOFOVIR; TENOFOVIR ALAFENAMIDE; UNINDEXED DRUG; VORINOSTAT; ZIDOVUDINE;

AGE; ARTICLE; BIRTH DEFECT; BONE DENSITY; BRAIN TUMOR; CONGENITAL HEART MALFORMATION; CORPUS CALLOSUM AGENESIS; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DISEASE TRANSMISSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC ASPECT; ETHNICITY; FOLLOW UP; GENE MUTATION; HEAD AND NECK DISEASE; HEALTH INSURANCE; HEALTH PROGRAM; HEART VENTRICLE SEPTUM DEFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCEPHALUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KIDNEY DISEASE; LOW BIRTH WEIGHT; MACROGYRIA; MORTALITY; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREMATURE LABOR; PREVALENCE; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STILLBIRTH;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEALTH SERVICES ADMINISTRATION; HIV INFECTIONS; HUMANS;

EID: 84878992601     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16(4):460-465.
2. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretrovi-ral therapy. Nature. 2012;487(7408):482-485.
3. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
4. Wilkin TJ, Lalama CM, McKinnon J, et al. A pilot trial of adding maraviroc to sup-pressive antiretroviral therapy for sub-optimal CD4(+) T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012;206(4):534-542.
5. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
6. Centers for Disease Control and Prevention (CDC). Vital signs: HIV prevention through care and treatment--United States. MMWR Morb Mortal Wkly Rep. 2011;60(47):1618-1623.
7. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. JAIDS. 2010;53(3):405-411.